Tick-borne Encephalitis
16
0
0
11
Key Insights
Highlights
Success Rate
92% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
6.3%
1 terminated out of 16 trials
91.7%
+5.2% vs benchmark
38%
6 trials in Phase 3/4
18%
2 of 11 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 11 completed trials
Clinical Trials (16)
Tick-borne Encephalitis Virus Research in Limousin
Serological Measurement of Montpellier Professionals' Contacts with Infectious Agents Responsible for Animal-borne Diseases
Study to Evaluate the Immunogenicity, Safety, and Tolerability of a Tick-Borne Encephalitis (TBE) Vaccine in Healthy Japanese Participants 1 Year of Age and Older
Primary TBE Vaccination for the Elderly
Prevalence of Tick-borne Encephalitis in the Pediatric Population Treated at the HUS and Characterization of Confirmed Pediatric Cases
New Study - Humoral Response to Tick-borne Encephalitis Vaccine in Elderly
Tick-borne Encephalitis and Positive Borrelial Antibodies
Cervicovaginal Immune Responses to 3 Deltoid or Thigh Intramuscular (IM) TicoVac
Vaccine Study for Tick-Borne Encephalitis Virus (TBEV)
Humoral Response to Tick-borne Encephalitis Vaccine in Elderly
Dose-finding Study to Investigate the Safety and Immunogenicity of Two Vaccinations With FSME IMMUN NEW in Healthy Volunteers Aged 6 to 16 Years.
Investigation of the Seropersistence of TBE Antibodies and the Booster Response to FSME-IMMUN 0.5 ml in Adults Aged 18 - 67 Years
Dose-finding Study to Investigate the Safety and Immunogenicity of Two Vaccinations With FSME IMMUN NEW in Healthy Volunteers Aged 1 to 6 Years.
Safety Study of FSME-IMMUN NEW in Healthy Children and Adolescents Aged 1 to 15 Years
Humoral and Cellular Immunity of Low and High-responders After Tick-borne Encephalitis Vaccination
Safety of and Immune Response to a Tick-Borne Encephalitis Vaccine (LGT(TP21)/DEN4) in Healthy Adults